In a historic policy shift, the FDA released more than 200 complete response letters (CRLs) issued from 2020 to 2024 concerning drug application rejections. The letters, although redacted and limited to drugs that eventually obtained approval, provide unprecedented insight into regulatory reasoning and common application deficiencies. This move aims to lessen uncertainty in drug development and aid sponsors in addressing review issues, marking a step toward greater agency openness.